Record Details

Identification of Novel Leishmania donovani Antigens that Help Define Correlates of Vaccine-Mediated Protection in Visceral Leishmaniasis

EPrints@IICB

View Archive Info
 
 
Field Value
 
Title Identification of Novel Leishmania donovani Antigens
that Help Define Correlates of Vaccine-Mediated
Protection in Visceral Leishmaniasis
 
Creator Bhowmick, Sutapa
Ali, Nahid
 
Subject Infectious Diseases and Immunology
 
Description Visceral leishmaniasis (VL), caused by the intracellular parasite Leishmania donovani is a major public health problem in the
developing world. But there is no effective and safe vaccine approved for clinical use against any form of leishmaniasis.
Through reactivity with kala-azar patient and cured sera, polypeptides ranging from 91 to 31-kDa from L. donovani
promastigotes were previously identified as potential protective vaccine candidates. In this study four polypeptides
91(LD91), 72 (LD72), 51(LD51) and 31 (LD31)-kDa were purified using sodium dodecyl sulfate polyacrylamide gel
electrophoresis followed by electroelution. We compared the vaccine efficacy of these antigens encapsulated in cationic
liposomes in BALB/c mice against challenge infection with L. donovani. Our results demonstrated that liposomal LD31 (74%–
77%) and LD51 (72%–75%) vaccination reduced parasite burden to the greatest degree followed by liposomal LD72 (65%–
67%) and LD91 (46%–49%). Analysis of the cytokine responses in immunized mice revealed that all the vaccinated groups
produced prechallenge interferon-c, interleukin-12 and interleukin-4. Interestingly, the degree of reduction in parasite load
could be predicted by the magnitude of the cytokine responses which correlated inversely with the parasite burden both in
liver and spleen. The 31, 51 and 72-kDa bands were identified as ATP synthase a chain, b-tubulin and heat shock 70-related
protein 1 precursor of L. major, respectively using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF/
TOF) mass spectrometry. These three leishmanial antigens have not been described before as successful vaccine candidates
examined against in vivo VL model. Thus, these antigens can be potential components of future antileishmaniasis vaccines.
 
Date 2009
 
Type Article
PeerReviewed
 
Format application/pdf
 
Identifier http://www.eprints.iicb.res.in/141/1/PLOS_ONE%2C_4_(6)%2C2009[58].pdf
Bhowmick, Sutapa and Ali, Nahid (2009) Identification of Novel Leishmania donovani Antigens that Help Define Correlates of Vaccine-Mediated Protection in Visceral Leishmaniasis. PLOS ONE, 4 (6).
 
Relation http://dx.doi.org/10.1371/journal.pone.0005820
http://www.eprints.iicb.res.in/141/